Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Purchased by Legacy Financial Advisors Inc.

Legacy Financial Advisors Inc. increased its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 13.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,774 shares of the medical equipment provider’s stock after buying an additional 216 shares during the period. Legacy Financial Advisors Inc.’s holdings in Intuitive Surgical were worth $598,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in ISRG. WCM Investment Management LLC purchased a new stake in Intuitive Surgical during the 4th quarter worth about $575,536,000. International Assets Investment Management LLC increased its stake in Intuitive Surgical by 32,360.5% in the fourth quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock valued at $231,721,000 after purchasing an additional 684,749 shares during the last quarter. Alphinity Investment Management Pty Ltd raised its holdings in Intuitive Surgical by 113.2% during the fourth quarter. Alphinity Investment Management Pty Ltd now owns 1,276,158 shares of the medical equipment provider’s stock worth $430,525,000 after purchasing an additional 677,455 shares in the last quarter. J.P. Morgan Private Wealth Advisors LLC purchased a new position in shares of Intuitive Surgical in the 3rd quarter valued at $178,667,000. Finally, Quadrature Capital Ltd raised its stake in Intuitive Surgical by 466.2% during the 3rd quarter. Quadrature Capital Ltd now owns 340,644 shares of the medical equipment provider’s stock worth $99,601,000 after acquiring an additional 280,480 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Price Performance

Shares of ISRG stock traded up $3.71 during midday trading on Friday, reaching $381.36. 1,028,858 shares of the company traded hands, compared to its average volume of 1,492,254. The firm’s 50 day simple moving average is $385.40 and its two-hundred day simple moving average is $349.30. The firm has a market cap of $135.27 billion, a PE ratio of 68.84, a price-to-earnings-growth ratio of 4.88 and a beta of 1.39. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. The company had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. Intuitive Surgical’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same period in the previous year, the business earned $1.00 earnings per share. As a group, research analysts anticipate that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current fiscal year.

Insider Transactions at Intuitive Surgical

In other news, Director Alan J. Levy sold 2,000 shares of the company’s stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total value of $741,400.00. Following the sale, the director now directly owns 25,319 shares in the company, valued at $9,385,753.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Intuitive Surgical news, VP Marshall Mohr sold 108,790 shares of the business’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total value of $41,892,853.20. Following the completion of the transaction, the vice president now directly owns 26,877 shares in the company, valued at approximately $10,349,795.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Alan J. Levy sold 2,000 shares of the firm’s stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total value of $741,400.00. Following the sale, the director now owns 25,319 shares in the company, valued at approximately $9,385,753.30. The disclosure for this sale can be found here. Insiders sold a total of 226,928 shares of company stock valued at $87,833,828 in the last ninety days. Corporate insiders own 0.90% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on ISRG shares. StockNews.com cut Intuitive Surgical from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Stifel Nicolaus lifted their target price on shares of Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a report on Monday, April 8th. Piper Sandler increased their price target on shares of Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a research note on Friday, April 19th. Wells Fargo & Company lifted their price objective on shares of Intuitive Surgical from $363.00 to $416.00 and gave the company an “overweight” rating in a research note on Friday, January 19th. Finally, Barclays increased their target price on shares of Intuitive Surgical from $385.00 to $430.00 and gave the stock an “overweight” rating in a research note on Thursday, January 25th. Five investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $396.17.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.